Prothena Corporation plc (NASDAQ:PRTA) released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday. AL (amyloid light-chain) amyloidosis is ...

Prothena Corporation PRTA reported first-quarter 2026 adjusted earnings per share (excluding restructuring costs) of 52 cents. The Zacks Consensus Estimate was a loss of 31 cents per share. In the ...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced ...

View Prothena Corp. Plc PRTA stock quote prices, financial information, real-time forecasts, and company news from CNN.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced ...

Prothena Corporation plc (NASDAQ:PRTA) shared results on Wednesday from the Phase 1 ASCENT clinical program in participants with early symptomatic Alzheimer’s disease (AD). As previously communicated, ...

Prothena Corporation plc ( NASDAQ:PRTA ) last week reported its latest quarterly results, which makes it a good ...

NEW YORK – Shares of Irish drug developer Prothena surged Friday after the company reported promising results from an early-stage study of a drug designed to treat Parkinson's disease. Prothena said ...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...